WHO ICTRP trial
Cure rate and side effects comparison between the sequential bismuth based…
ACTRN12615000493549 · Australian New Zealand Clinical Trials Registry (ANZCTR) · Not Recruiting
Key facts
| Trial ID | ACTRN12615000493549 |
|---|---|
| Public title | Cure rate and side effects comparison between the sequential bismuth based quadruple therapy and the concomitant bismuth based quadruple therapy in treating patients carrying antibiotic resistant Helicobacter pylori strain. |
| Scientific title | Efficacy of sequential bismuth based quadruple therapy versus concomitant bismuth based quadruple therapy in treating patients carrying antibiotic resistant Helicobacter pylori strain. |
| Primary sponsor | University of Western Australia |
| Registry | Australian New Zealand Clinical Trials Registry (ANZCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase 4 |
| Countries | Australia |
| Conditions | Helicobacter pylori unable to be eradicated with standard triple therapies.; Helicobacter pylori unable to be eradicated with standard triple therapies.;Oral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive… |
| Interventions | sequential treatment (5 days of rabeprazole 20 mg three times a day and bismuth subcitrate (BIS) 240mg four times a day, followed by 5 days of rabeprazole 20 mg three times a day, BIS 240mg four times a day, rifabutin (RFB) 150 mg twice a… |
| Registration date | May 19, 2015 |
| Target size | 200 |
| Secondary IDs | Nil known |
| Registry page | anzctr.org.au |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: